HOME >> MEDICINE >> NEWS
One dose of 'designer' gene therapy may target specific body area

DALLAS, Jan. 20 Doctors may soon be able to inject gene therapy intravenously that travels to a specific part of the body, according to a study published in today's rapid access issue of Circulation: Journal of the American Heart Association.

"It may be possible to design and construct genetically engineered 'designer' gene therapy for selectively delivering genes to any part of the body," said Andrew H. Baker, Ph.D., lead investigator of the study and a reader in molecular medicine at the University of Glasgow in Scotland. "We can't do that now because much of what's injected would be sequestered by the liver." The liver cleanses the blood of foreign material, among other functions.

Gene therapy involves inserting the treatment genes into a virus that is either harmless to humans or has had its disease-causing component removed. The virus is then injected or inserted into the body where it "infects" an area with gene therapy.

Baker's team redesigned a virus called adeno-associated virus (AAV) so that it is not quarantined by the liver, but rather remained in the bloodstream long enough to "infect" specific cells in the body -- in this case, the vascular endothelial cells (ECs). The new therapy targets vascular endothelial cells, which line the inside of blood vessels.

"Vascular endothelial cells, which are in continuous contact with the bloodstream and integrally involved in cardiovascular abnormalities, are appropriate targets for gene therapy," Baker said.

Baker said that AAV is important because it has the potential for long-term gene expression from a single dose. This is based on results from hemophilia studies from other laboratories in which the virus was used to deliver gene therapy. In these studies, Baker said that a single dose could last up to five years, possibly longer as the studies are ongoing. AAV is also a good choice because it does not cause disease in humans.

"The concept of developing systematica
'"/>

Contact: Carole Bullock
carole.bullock@heart.org
214-706-1279
American Heart Association
19-Jan-2004


Page: 1 2

Related medicine news :

1. Study shows patch therapy may be as effective as oral medications
2. Novel therapy tested in mice could chase away cat allergies
3. Drug therapy may be comparable to invasive cardiac procedures for elderly patients with heart attack
4. Risk of cardiac death after radiotherapy for breast cancer has declined, study finds
5. Antiretroviral therapy may prevent excess risk of some cancers in people with HIV
6. Bevacizumab combined with chemotherapy prolongs survival for some patients with advanced lung cancer
7. Breakthrough in medical research: New chemotherapy gives hope to brain tumour patients
8. Two years after gene therapy treatments, severe angina patients showed prolonged clinical benefit
9. Combining PET and CT scans leads to more accurate radiation therapy for lung cancer patients
10. Cognitive behavioral therapy and medication is effective in the treatment of panic disorder
11. Study finds drug eluting stents as effective as vascular brachytherapy in preventing restenosis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/20/2017)... Ashburn, Virginia (PRWEB) , ... September 20, 2017 ... ... Spartacote Flex Pure Clinical Plus Coating System for clients that rely on safety ... inhibit the growth of microorganisms. , Silver has been used for centuries for ...
(Date:9/20/2017)... ... September 20, 2017 , ... Mirror ... fall event , Look Awesome This Autumn with CoolSculpting®. Scheduled for Thursday, September ... refreshments. , Mirror Mirror Beauty Boutique is Houston’s largest CoolSculpting ...
(Date:9/20/2017)... Trenton, NJ (PRWEB) , ... September 20, 2017 ... ... and a variety of settings, gather for the National Athletic Trainers’ Association Annual ... displayed and case studies presented. It is also when Athletic Trainers are acknowledged ...
(Date:9/20/2017)... ... September 20, 2017 , ... Medicare doesn’t ... risk of price gouging for their prescription drugs, according to a new comparison ... isn’t negotiating on our behalf, there’s no consistency in drug pricing among drug ...
(Date:9/20/2017)... ... ... “Finn Mouseson”: follows the exciting story of a mouse as the need for ... a journey that will show that friends are to be gathered but home is ... illustrator, Melody Gersonde-Mickelson, who has earned a bachelor’s degree in Fine Arts from the ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... Sept. 6, 2017 Eli Lilly and Company ... present new data for galcanezumab and lasmiditan, two investigational ... International Headache Society (IHC) taking place Sept. 7-10 in ... will highlight new, long-term data from an open-label study ... galcanezumab (120 mg and 240 mg) for the prevention ...
(Date:9/5/2017)... Inc. has announced another milestone in their continued growth and success of the ... demands of customer engagements regionally.  ... office is located at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest office ... In addition ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
Breaking Medicine Technology:
Cached News: